- Home
- LAZ vs GH Comparison
LAZ vs GH Comparison
Compare LAZ & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAZ
- GH
- Stock Information
- Founded
- LAZ 1848
- GH 2011
- Country
- LAZ United States
- GH United States
- Employees
- LAZ N/A
- GH N/A
- Industry
- LAZ Investment Managers
- GH Medical Specialities
- Sector
- LAZ Finance
- GH Health Care
- Exchange
- LAZ Nasdaq
- GH Nasdaq
- Market Cap
- LAZ 4.1B
- GH 4.9B
- IPO Year
- LAZ 2005
- GH 2018
- Fundamental
- Price
- LAZ $42.93
- GH $42.10
- Analyst Decision
- LAZ Hold
- GH Strong Buy
- Analyst Count
- LAZ 7
- GH 21
- Target Price
- LAZ $44.33
- GH $52.81
- AVG Volume (30 Days)
- LAZ 941.6K
- GH 2.2M
- Earning Date
- LAZ 07-24-2025
- GH 04-30-2025
- Dividend Yield
- LAZ 4.66%
- GH N/A
- EPS Growth
- LAZ N/A
- GH N/A
- EPS
- LAZ 2.87
- GH N/A
- Revenue
- LAZ $2,939,019,000.00
- GH $773,996,000.00
- Revenue This Year
- LAZ N/A
- GH $23.05
- Revenue Next Year
- LAZ $14.61
- GH $21.40
- P/E Ratio
- LAZ $14.92
- GH N/A
- Revenue Growth
- LAZ 7.18
- GH 28.20
- 52 Week Low
- LAZ $31.97
- GH $20.14
- 52 Week High
- LAZ $61.14
- GH $52.92
- Technical
- Relative Strength Index (RSI)
- LAZ 49.75
- GH 53.22
- Support Level
- LAZ $41.60
- GH $37.73
- Resistance Level
- LAZ $44.81
- GH $39.63
- Average True Range (ATR)
- LAZ 1.29
- GH 1.63
- MACD
- LAZ -0.25
- GH 0.24
- Stochastic Oscillator
- LAZ 23.84
- GH 93.18
About LAZ Lazard Inc.
Lazard has a storied history that can be traced back to 1848. The company's revenue is fairly evenly split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily driven by equities (over 80% of assets under management), has an international focus, and targets institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.